Skip to main content

West Pharmaceutical Services ratios

  • WST · NYSE
  • Medical devices
  • Health Care Supplies
  • S&P 500
$416.42+1.24%Close 13 Nov 2026

In fiscal 2025 (the year to 31 Dec 2025), West Pharmaceutical Services had an operating margin of 19.0%, a return on equity of 16.9%, a return on invested capital of 16.7%.

From West Pharmaceutical Services's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

West Pharmaceutical Services ratios, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin28.8%28.8%28.8%28.5%30.6%31.8%31.5%32.6%33.2%32.1%31.8%32.9%35.8%41.5%39.4%38.3%34.5%35.9%
Operating margin11.8%9.2%8.2%9.2%10.7%11.9%12.8%9.2%12.9%14.1%14.0%16.1%19.0%26.6%25.4%22.9%19.7%19.0%
Net margin8.2%6.9%5.9%6.3%6.4%8.2%8.9%6.8%9.5%9.4%12.0%13.1%16.1%23.4%20.3%20.1%17.0%16.1%
Free cash flow margin−0.3%3.1%6.1%3.0%4.4%5.0%5.0%5.8%3.3%8.3%10.7%13.1%13.9%11.7%15.2%14.1%9.6%15.3%
Return on equity17.7%13.6%10.8%11.8%11.7%13.7%13.6%9.7%13.4%12.6%15.5%16.3%20.2%31.6%23.3%21.3%17.7%16.9%
Return on assets—6.4%5.8%6.1%6.4%7.3%7.9%5.9%8.2%8.0%10.4%11.0%13.0%21.1%17.6%15.0%12.5%11.8%
Return on capital employed—8.9%8.2%9.6%11.0%11.9%12.8%9.2%13.7%14.8%14.7%16.1%19.0%30.0%25.2%21.6%18.2%17.4%
Return on invested capital—8.0%7.3%7.8%8.4%10.0%11.0%8.4%11.4%10.9%14.6%15.9%20.0%33.9%28.1%23.3%18.0%16.7%
Current ratio—2.322.571.942.132.752.612.142.662.663.153.102.732.933.702.882.793.02
Debt to equity—0.660.570.530.560.410.350.290.200.150.140.210.180.140.120.110.110.10
Net debt / EBITDA—1.841.511.251.120.550.290.110.09−0.12−0.41−0.27−0.56−0.50−0.67−0.67−0.25−0.62
Interest coverage7.766.415.406.028.099.5511.039.1224.1028.9528.6134.8949.6291.7492.9175.11189.971169.80
Cash conversion−4.2%45.2%103%46.8%69.5%61.1%55.9%84.5%34.3%87.9%88.9%99.6%86.1%50.0%75.0%69.9%56.1%95.0%
Dividend payout21.6%27.7%33.2%30.7%30.9%23.8%22.9%33.9%24.9%25.9%20.3%18.7%13.9%7.7%9.2%9.6%12.0%12.4%
SBC / Revenue0.6%0.7%0.7%0.7%1.2%1.5%1.3%2.1%1.3%1.0%0.9%1.3%1.6%1.3%0.8%0.8%0.6%0.8%

Quarterly

West Pharmaceutical Services ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Gross margin38.0%33.1%32.8%35.4%36.5%33.2%35.7%36.6%37.8%35.1%37.7%39.7%
Operating margin22.0%17.7%18.0%21.6%21.3%15.3%20.1%20.8%19.5%21.0%20.5%30.6%
Net margin18.7%16.6%15.9%18.2%17.4%12.9%17.2%17.4%16.4%16.4%17.7%24.5%
Free cash flow margin17.8%4.0%9.2%13.2%11.4%8.3%13.3%16.6%21.7%5.6%9.3%17.2%
Return on equity4.8%4.3%4.3%4.9%4.9%3.3%4.5%4.6%4.2%4.6%5.2%7.2%
Return on assets3.3%3.0%3.0%3.5%3.4%2.3%3.1%3.3%2.9%3.2%3.6%5.2%
Return on capital employed5.1%4.2%4.4%5.1%5.2%3.5%4.6%4.8%4.3%5.2%5.2%7.8%
Return on invested capital5.1%4.3%4.1%4.8%4.6%3.1%4.3%4.7%4.3%4.5%4.9%7.0%
Current ratio2.882.612.343.002.792.772.782.873.022.712.822.82
Debt to equity0.110.110.120.110.110.110.100.100.100.110.100.10
Net debt / EBITDA−2.77−1.86−0.82−0.92−0.91−0.69−1.06−1.57−2.31−0.92−0.55−0.51
Interest coverage134.0876.7584.13230.43199.50267.501537.00838.00783.0093.2168.8870.37
Cash conversion95.2%23.9%58.2%72.6%65.5%64.7%77.3%95.6%132%34.0%52.5%70.3%
Dividend payout10.8%12.7%13.1%10.7%11.8%16.9%11.5%10.8%12.0%11.4%10.2%7.2%
SBC / Revenue0.2%0.7%0.6%0.7%0.6%0.2%1.0%1.0%0.8%0.8%1.2%0.5%

The main figures as JSON and plain text. See data and methodology.

WST in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.